Literature DB >> 10877378

Relationship between the effect of carbon dioxide inhalation or nilvadipine on orbital blood flow in normal-tension glaucoma.

Y Niwa1, T Yamamoto, A Harris, L Kagemann, H Kawakami, Y Kitazawa.   

Abstract

PURPOSE: To investigate the relationship between the effect of carbon dioxide (CO2) inhalation or oral nilvadipine, a calcium-channel blocker, on orbital blood flow in patients with normal-tension glaucoma, as determined by color Doppler imaging. PATIENTS AND METHODS: Sixteen patients with normal-tension glaucoma (mean age, 55.6+/-9.8 years; male:female ratio, 3:13) underwent color Doppler imaging to measure the resistance index, and peak systolic and end-diastolic blood flow velocities of the ophthalmic artery, central retinal artery, and nasal and temporal short posterior ciliary arteries. Measurements were taken before and during CO2 supplementation sufficient to increase the end-tidal CO2 partial pressure by 10%. The color Doppler imaging measurements were repeated after 2 to 4 weeks of treatment with 2 mg oral nilvadipine, and comparisons were made between the effects of the two treatments.
RESULTS: Both CO2 inhalation and nilvadipine treatment significantly reduced the resistance index in the central retinal artery, nasal short posterior ciliary artery, and temporal short posterior ciliary artery. There was a significant correlation between the effects of the two treatments on the difference in the resistance indexes of the ophthalmic artery and central retinal artery, but not on those of the nasal or temporal short posterior ciliary artery.
CONCLUSIONS: Both CO2 inhalation and oral nilvadipine significantly reduce the resistance index measured by color Doppler imaging in orbital vessels. The effect of oral nilvadipine might be predicted by CO2 inhalation in patients with normal-tension glaucoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10877378     DOI: 10.1097/00061198-200006000-00010

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  9 in total

1.  [Color Doppler sonography of retrobulbar vessels and hypercapnia in normal tension glaucoma].

Authors:  N Plange; M Bienert; A Harris; A Remky; K O Arend
Journal:  Ophthalmologe       Date:  2012-03       Impact factor: 1.059

2.  Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma.

Authors:  A Luksch; G Rainer; D Koyuncu; P Ehrlich; T Maca; M E Gschwandtner; C Vass; L Schmetterer
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

3.  [Primary open-angle glaucoma and systemic diseases].

Authors:  M Pache
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

4.  Ocular haemodynamic responses to induced hypercapnia and hyperoxia in glaucoma.

Authors:  S L Hosking; A Harris; H S Chung; C P Jonescu-Cuypers; L Kagemann; E J Roff Hilton; H Garzozi
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

5.  The effect of latanoprost on ocular blood flow.

Authors:  Alon Harris; Hanna J Garzozi; Lynne McCranor; Ehud Rechtman; Chi-Wah Yung; Brent Siesky
Journal:  Int Ophthalmol       Date:  2008-02-23       Impact factor: 2.031

6.  Dysfunctional regulation of ocular blood flow: A risk factor for glaucoma?

Authors:  Danny Moore; Alon Harris; Darrell Wudunn; Nisha Kheradiya; Brent Siesky
Journal:  Clin Ophthalmol       Date:  2008-12

Review 7.  Glaucomatous optic neuropathy management: the role of neuroprotective agents.

Authors:  Marianne L Shahsuvaryan
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013

8.  Nimodipine inhibits N-methyl-N-nitrosourea-induced retinal photoreceptor apoptosis in vivo.

Authors:  Dan Wang; Zhuo Wang; Yan Li; Xin Chen; Gui Yuan Sun
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

9.  Nimodipine rescues N-methyl-N-nitrosourea-induced retinal degeneration in rats.

Authors:  Dan Wang; Yan Li; Zhuo Wang; Gui-Yuan Sun; Qiu-Hua Zhang
Journal:  Pharmacogn Mag       Date:  2013-04       Impact factor: 1.085

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.